APYX Fundamental Analysis - APYX MEDICAL CORP

Fundamental Rating

Taking everything into account, APYX scores 2 out of 10 in our fundamental rating. APYX was compared to 186 industry peers in the Health Care Equipment & Supplies industry. APYX may be in some trouble as it scores bad on both profitability and health. APYX is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year APYX has reported negative net income.
APYX had a negative operating cash flow in the past year.
In the past 5 years APYX always reported negative net income.
APYX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -25.35%, APYX is in line with its industry, outperforming 47.31% of the companies in the same industry.
APYX's Return On Equity of -248.63% is on the low side compared to the rest of the industry. APYX is outperformed by 74.19% of its industry peers.

		Industry Rank	Sector Rank
ROA	-25.35%
ROE	-248.63%
ROIC	N/A

ROA(3y)-34.86%

ROA(5y)-28.54%

ROE(3y)-98.96%

ROE(5y)-68.76%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 62.65%, APYX is in the better half of the industry, outperforming 65.05% of the companies in the same industry.
In the last couple of years the Gross Margin of APYX has declined.
The Profit Margin and Operating Margin are not available for APYX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	62.65%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-4.12%

GM growth 5Y-2.02%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

APYX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for APYX has been increased compared to 1 year ago.
The number of shares outstanding for APYX has been increased compared to 5 years ago.
Compared to 1 year ago, APYX has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of 0.84, we must say that APYX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.84, APYX perfoms like the industry average, outperforming 49.46% of the companies in the same industry.
A Debt/Equity ratio of 5.92 is on the high side and indicates that APYX has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 5.92, APYX is doing worse than 85.48% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	5.92
Debt/FCF	N/A
Altman-Z	0.84

ROIC/WACCN/A

WACC10.97%

2.3 Liquidity

APYX has a Current Ratio of 4.44. This indicates that APYX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.44, APYX is in the better half of the industry, outperforming 74.73% of the companies in the same industry.
A Quick Ratio of 3.61 indicates that APYX has no problem at all paying its short term obligations.
APYX's Quick ratio of 3.61 is fine compared to the rest of the industry. APYX outperforms 73.12% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.44
Quick Ratio	3.61

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 56.63% over the past year.
APYX shows a decrease in Revenue. In the last year, the revenue decreased by -1.32%.
Measured over the past years, APYX shows a quite strong growth in Revenue. The Revenue has been growing by 11.24% on average per year.

EPS 1Y (TTM)56.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%64.29%

Revenue 1Y (TTM)-1.32%

Revenue growth 3Y-0.29%

Revenue growth 5Y11.24%

Sales Q2Q%12.1%

3.2 Future

Based on estimates for the next years, APYX will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.24% on average per year.
Based on estimates for the next years, APYX will show a very strong growth in Revenue. The Revenue will grow by 41.40% on average per year.

EPS Next Y52.46%

EPS Next 2Y19.89%

EPS Next 3Y14.41%

EPS Next 5Y18.24%

Revenue Next Year9.08%

Revenue Next 2Y7.88%

Revenue Next 3Y7.5%

Revenue Next 5Y41.4%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

APYX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year APYX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as APYX's earnings are expected to grow with 14.41% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y19.89%

EPS Next 3Y14.41%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for APYX!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

APYX MEDICAL CORP

NASDAQ:APYX (1/16/2026, 8:00:01 PM)

After market: 3.99 0 (0%)

3.99

+0.1 (+2.57%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)11-06 2025-11-06/bmo

Earnings (Next)03-11 2026-03-11/amc

Inst Owners37.8%

Inst Owner Change0.3%

Ins Owners13.42%

Ins Owner Change0%

Market Cap163.63M

Revenue(TTM)47.90M

Net Income(TTM)-14.54M

Analysts80

Price Target5.87 (47.12%)

Short Float %0.31%

Short Ratio1.05

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)28.82%

Min EPS beat(2)5.46%

Max EPS beat(2)52.18%

EPS beat(4)4

Avg EPS beat(4)25.6%

Min EPS beat(4)5.46%

Max EPS beat(4)52.18%

EPS beat(8)6

Avg EPS beat(8)9.91%

EPS beat(12)7

Avg EPS beat(12)1.81%

EPS beat(16)9

Avg EPS beat(16)3.5%

Revenue beat(2)1

Avg Revenue beat(2)0.25%

Min Revenue beat(2)-4.69%

Max Revenue beat(2)5.19%

Revenue beat(4)2

Avg Revenue beat(4)0.78%

Min Revenue beat(4)-4.69%

Max Revenue beat(4)5.19%

Revenue beat(8)4

Avg Revenue beat(8)0.71%

Revenue beat(12)5

Avg Revenue beat(12)-1.66%

Revenue beat(16)7

Avg Revenue beat(16)-1.7%

PT rev (1m)1.47%

PT rev (3m)43.75%

EPS NQ rev (1m)1.71%

EPS NQ rev (3m)-13.18%

EPS NY rev (1m)-0.73%

EPS NY rev (3m)15.61%

Revenue NQ rev (1m)2.33%

Revenue NQ rev (3m)4.11%

Revenue NY rev (1m)0.8%

Revenue NY rev (3m)3.14%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	3.42
P/FCF	N/A
P/OCF	N/A
P/B	27.98
P/tB	27.98
EV/EBITDA	N/A

EPS(TTM)-0.36

EYN/A

EPS(NY)-0.38

Fwd EYN/A

FCF(TTM)-0.23

FCFYN/A

OCF(TTM)-0.21

OCFYN/A

SpS1.17

BVpS0.14

TBVpS0.14

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-25.35%
ROE	-248.63%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	62.65%
FCFM	N/A

ROA(3y)-34.86%

ROA(5y)-28.54%

ROE(3y)-98.96%

ROE(5y)-68.76%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-4.12%

GM growth 5Y-2.02%

F-Score4

Asset Turnover0.84

Health

		Industry Rank	Sector Rank
Debt/Equity	5.92
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	188.19%
Cap/Sales	2.26%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.44
Quick Ratio	3.61
Altman-Z	0.84

F-Score4

WACC10.97%

ROIC/WACCN/A

Cap/Depr(3y)103.68%

Cap/Depr(5y)91.24%

Cap/Sales(3y)1.6%

Cap/Sales(5y)1.67%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)56.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%64.29%

EPS Next Y52.46%

EPS Next 2Y19.89%

EPS Next 3Y14.41%

EPS Next 5Y18.24%

Revenue 1Y (TTM)-1.32%

Revenue growth 3Y-0.29%

Revenue growth 5Y11.24%

Sales Q2Q%12.1%

Revenue Next Year9.08%

Revenue Next 2Y7.88%

Revenue Next 3Y7.5%

Revenue Next 5Y41.4%

EBIT growth 1Y55.94%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year76.62%

EBIT Next 3Y22.44%

EBIT Next 5Y28.09%

FCF growth 1Y-16.47%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-11.07%

OCF growth 3YN/A

OCF growth 5YN/A

APYX MEDICAL CORP / APYX FAQ

Can you provide the ChartMill fundamental rating for APYX MEDICAL CORP?

ChartMill assigns a fundamental rating of 2 / 10 to APYX.

What is the valuation status for APYX stock?

ChartMill assigns a valuation rating of 0 / 10 to APYX MEDICAL CORP (APYX). This can be considered as Overvalued.

What is the profitability of APYX stock?

APYX MEDICAL CORP (APYX) has a profitability rating of 1 / 10.

APYX MEDICAL CORP (APYX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

APYX MEDICAL CORP / APYX FAQ

Can you provide the ChartMill fundamental rating for APYX MEDICAL CORP?

What is the valuation status for APYX stock?

What is the profitability of APYX stock?